Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Priothera – US FDA grants Orphan Drug Designation to mocravimod to improve the outcome of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with hematologic malignancies

Related Keywords

Massachusetts ,United States ,France ,Dublin ,Ireland ,Boston ,Sweden ,Berlin ,Germany ,America ,Florent Gros ,Drug Administration ,Tekla Capital Management ,European Investment Bank ,Priothera Ltd ,Orphan Drug ,Acute Myeloid Leukemia ,Southeast Asia ,Fountain Healthcare Partners ,Earlybird Venture Capital ,Venture Debt Instrument ,Grand Est Bpifrance ,